Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Accelerate to discover
Back to filter
Show all topics (10)
Related topics
Recent publication of in-vivo two-photon intravital imaging study targeting mouse kidney
May 22, 2023
In vivo longitudinal 920 nm two-photon intravital kidney imaging of a dynamic 2,8-DHA crystal
formation and...
Webinar: Multimodal tissue imaging and machine learning to advance precision medicine
May 17, 2023
Join us for this webinar to learn how the Orion spatial biology imaging platform was used to identify prognostic...
May 5, 2023
Decision to improve the output in a lab is always taken based on knowledge and workflow needs. But final decision to...
Real-Time and Quantitative Analysis of Macrophage Phagocytosis with RTCA eSight
May 4, 2023
The eSight is currently the only instrument that interrogates cell health and behavior using cellular
impedance...
Revolutionize your Flow Cytometry and Sorting workflow with Cytek Biosciences
May 3, 2023
Using full spectrum flow cytometry, Cytek systems ( RUO and CE-IVD) detect the entire fluorochrome emission, allowing...
A deep learning and Monte Carlo based framework for bioluminescence imaging center Maastro
Apr 20, 2023
"In this paper,we developed a framework using deep learning for bioluminescence-based targeting for GBM animal...
Gentle sorting of microbial cells and sub-micron particles using WOLF sorter
Apr 18, 2023
While most modern applications of flow cytometry may focus on cells of eukaryotic origin, the first flow analyzers were...
Simultaneous non-invasive in vivo imaging of apoptosis and angiogenesis in a mouse model
Oct 20, 2016
Baseline angiogenesis and apoptotic activities were simultaneous evaluated before initiation of the treatment (D0) using the Bruker In-Vivo Xtreme imaging system, after i.p. administration of Angiosense680 EX and Annexin750 probes, respectively, according to the instructions of the supplier. After 3 days of treatment (D3), angiogenesis and apoptotic activities were similarly assessed; GLPG1790, Flavopiridol or Bevacizumab treatments were given 2hr prior to imaging.
All images were captured by a cooled CCD camera with the following parameters: f-stop 1.1, binning 2, 2 sec acquisition time for Angiosense680 EX and 5 sec acquisition time for Annexin750.
For anatomical co-registration, a reflectance image (0.1 second acquisition time, f-stop 2.8, binning 1) and an X-ray image (1.2 second acquisition time, f-stop 4, 45 KVP energy, 2 mm filter) were performed.
For precise co-registration, all images were taken with a 190 mm field of view (FOV). For each mouse and each probe, results were expressed as the difference between Net intensity at D3 and D0.
Related technologies: Fluorescence, luminescence, X-ray, radiographic imaging
Get more info
Brand profile
